Enovis acquires eCential Robotics for €155 million

Enovis, a leading medical technology company, is expanding its innovative capabilities by acquiring eCential Robotics, a pioneering developer of enabling technologies and surgical robotics. The acquisition is set to bolster Enovis’s ASTRA enabling technology platform with advanced robotic automation, enhancing surgical precision and operational efficiency.

Enovis announced on September 1, 2026, that it has entered into a binding agreement to purchase eCential Robotics for an upfront enterprise value of €155 million, with an additional €35 million contingent on meeting specific milestones. The deal is expected to close by the end of 2026, subject to regulatory approvals.

The transaction will see Enovis integrate eCential Robotics into its operations, creating a robotics center of excellence in Grenoble, France. This move aligns with Enovis’s strategy to leverage talent in a key medical technology hub and advance its robotic innovation roadmap. Founded in 2008, eCential Robotics has developed a modular platform for robotic-assisted surgery, focusing on computer-assisted surgery and orthopedic robotics.

Damien McDonald, CEO of Enovis, commented, "This acquisition is a significant milestone and reflects our commitment to bringing external innovation into Enovis. The eCential Robotics team brings exceptional engineering talent, intellectual property, and a proven track record of bringing innovative robotic solutions to market. Their expertise will serve as the cornerstone of our robotics strategy and enable Enovis to lead in surgical enabling technology."

Clément Vidal, CEO of eCential Robotics, added, "Our strategy has always been to offer surgeons easy-to-use, cutting-edge technology to improve surgical workflows and ultimately enable better patient outcomes. As part of Enovis, we will be able to grow through a shared mission to support surgeons with greater operating room efficiency and help patients live more full, active lives."

Stéphane Lavallée, founder and chair of eCential Robotics, stated, "I am excited about the next chapter for eCential Robotics. Enovis brings focus, speed, and a real commitment to the future of eCential Robotics. Together, the combined companies will continue to support existing partnerships and build a center of excellence for robotics in Grenoble."

The acquisition is expected to have a modest impact on Enovis’s adjusted EBITDA margin, with a 100 basis point headwind in 2027, offset by underlying improvements. Enovis anticipates free cash flow conversion to increase to 50% in 2027, reaching over $100 million in the following years.

Latham & Watkins LLP is serving as legal counsel to Enovis in connection with the transaction. Enovis will host an investor conference call on the same day to discuss the acquisition, with details available on the company’s website.

Enovis’s focus on integrating eCential Robotics aims to create a comprehensive ecosystem for surgical robotics, enhancing precision and streamlining workflows. The combined expertise will position Enovis to deliver advanced robotic solutions that support surgeons and improve patient outcomes.